• Please Remember: Members are only permitted to share their own experiences. Members are not qualified to give medical advice. Additionally, everyone manages their health differently. Please be respectful of other people's opinions about their own diabetes management.
  • We seem to be having technical difficulties with new user accounts. If you are trying to register please check your Spam or Junk folder for your confirmation email. If you still haven't received a confirmation email, please reach out to our support inbox: support.forum@diabetes.org.uk

One-shot lifetime cholesterol lowering - getting closer

Eddy Edson

Eddy Edson

Well-Known Member
Relationship to Diabetes
In remission from Type 2
Lily is buying start-up Verve Therapeutics, whose one-shot gene editing technology is showing promise of lifetime 50%+ reductions in LDL-C in early trials.


"VERVE-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development.

(Still some risk, and anyway years to market. Plenty of time for the people in the business of spreading statin misinformation to plan ahead for this new target.)
 
You must log in or register to reply here.
Back
Top